

Preferred Drug List Announcement

MO HealthNet Division (MHD) is continuing the state-specific Preferred Drug List (PDL) evaluation process. Drug/Drug classes for review for the upcoming quarter are identified at each of the quarterly meetings of the Drug Prior Authorization Committee and also posted on the Division’s web page at <http://dss.mo.gov/mhd/cs/pharmacy/pdf/pdla.pdf> shortly following each meeting.

MO HealthNet Division’s clinical team will conduct the clinical reviews of the drug products under evaluation each quarter. For preferred status consideration for your product, a more detailed review request should be presented to MHD.

- All clinical information for consideration should be forwarded to Karen Powell at karen.powell@gainwelltechnologies.com. These submissions should generally follow the AMCP guideline format.
- Financial evaluations for these therapeutic class reviews are conducted by Gainwell Technologies, LLC. Companies wishing to discuss opportunities for supplemental rebates and/or the policy surrounding the PDL process should contact Sandy Kapur, PharmD at sandy.kapur@gainwelltechnologies.com.
- If a public presentation is desired, please contact Carmen Burton at Carmen.M.Burton@dss.mo.gov or call (573) 751-6961.

The Drug PA Committee will convene at 10:00 a.m. on Thursday, September 15, 2022.

Drug Therapeutic Class Name	
<input type="checkbox"/> ACE Inhibitors & ACE Inhibitor Diuretic Combination Agents	<input type="checkbox"/> Beta Blockers & Beta Blockers/Diuretic Combinations
<input type="checkbox"/> ACE Inhibitors/CCB Combinations	<input type="checkbox"/> Biguanides and Combination Agents
<input type="checkbox"/> ADHD, Amphetamines Long Acting	<input type="checkbox"/> Bile Salt Agents
<input type="checkbox"/> ADHD, Amphetamines Short Acting	<input type="checkbox"/> Bone Ossification Agents
<input type="checkbox"/> ADHD, Methylphenidate Long Acting	<input type="checkbox"/> CCB Agents, Dihydropyridines
<input type="checkbox"/> ADHD, Methylphenidate Short Acting	<input type="checkbox"/> CCB Agents, Non-Dihydropyridines
<input type="checkbox"/> ADHD, Non-Stimulants	<input type="checkbox"/> Cephalosporins
<input type="checkbox"/> Alpha-Glucosidase Inhibitors	<input type="checkbox"/> Colony Stimulating Factors
<input type="checkbox"/> Amylin Analogs	<input type="checkbox"/> Cryopyrin-Associated Periodic Syndrome Agents
<input type="checkbox"/> Antibiotics, GI Oral	<input type="checkbox"/> Direct Renin Inhibitors & Combinations
<input type="checkbox"/> Antibiotics, Mupirocin Topical	<input type="checkbox"/> DPP-IV Inhibitors and Combination Agents
<input type="checkbox"/> Antibiotics, Vaginal	<input type="checkbox"/> Dry Eye Disease Agents
<input type="checkbox"/> Anticoagulants, Oral & SQ	<input type="checkbox"/> Electrolyte Depleters, Phosphate Lowering
<input type="checkbox"/> Anticonvulsants, Rescue Agents	<input type="checkbox"/> Electrolyte Depleters, Potassium Lowering
<input type="checkbox"/> Antihyperuricemic Agents	<input type="checkbox"/> Erythropoiesis Stimulating Agents
<input type="checkbox"/> Antiplatelets	<input type="checkbox"/> Fluoroquinolones, Oral
<input type="checkbox"/> ARB & ARB/Diuretic Combinations	<input type="checkbox"/> GI Antibiotics, Oral
<input type="checkbox"/> ARB/CCB Combination Agents	<input type="checkbox"/> GLP-1 Receptor Agonists
<input type="checkbox"/> Benign Prostatic Hyperplasia Agents	

Drug Therapeutic Class Name

<input type="checkbox"/> Growth Hormone Agents, Somatropin <input type="checkbox"/> Growth Hormone and Growth Hormone Releasing Factors, Select Agents <input type="checkbox"/> Homozygous Familial Hypercholesterolemia (HoFH) Agents <input type="checkbox"/> Insulin, Long Acting <input type="checkbox"/> Insulin, Mixed <input type="checkbox"/> Insulin, Non-Analogs <input type="checkbox"/> Insulin, Rapid Acting <input type="checkbox"/> LHRH, GHRH Antagonists, Injectable <input type="checkbox"/> LHRH, GHRH Antagonists, Oral <input type="checkbox"/> Macrolides <input type="checkbox"/> Meglitinides <input type="checkbox"/> Methotrexate Agents <input type="checkbox"/> Multiple Sclerosis Agents, Injectable <input type="checkbox"/> Multiple Sclerosis Agents, Oral <input type="checkbox"/> Niacin Derivatives <input type="checkbox"/> PAH, Endothelin Receptor Antagonists (ETRA) Oral <input type="checkbox"/> PAH, Phosphodiesterase-5 (PDE5) Inhibitors & Soluble Guanylate Cyclase (SGC) Oral <input type="checkbox"/> PAH, Prostacyclins Inhaled <input type="checkbox"/> PAH, Prostacyclins Injectable <input type="checkbox"/> PAH, Prostacyclins Oral <input type="checkbox"/> Penicillins <input type="checkbox"/> Pregnancy Maintaining Agents, Hormonal <input type="checkbox"/> Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) Binders	<input type="checkbox"/> Proton Pump Inhibitors <input type="checkbox"/> SGLT2 Inhibitors and Combination Agents <input type="checkbox"/> Spinal Muscular Atrophy Agents <input type="checkbox"/> Statins (HMG Co-A Reductase Inhibitors) & Combination Agents <input type="checkbox"/> Sulfonylureas, Second Generation <input type="checkbox"/> Sympatholytic Agents <input type="checkbox"/> Targeted Immune Modulators, IL-17A Antibody/IL-17 Receptor Antagonists <input type="checkbox"/> Targeted Immune Modulators, IL-23 Inhibitors and IL-23/IL-12 Inhibitors <input type="checkbox"/> Targeted Immune Modulators, IL-6 Receptor Inhibitors <input type="checkbox"/> Targeted Immune Modulators, JAK Inhibitors <input type="checkbox"/> Targeted Immune Modulators, Miscellaneous Allergy- and Asthma-Related Monoclonal Antibodies <input type="checkbox"/> Targeted Immune Modulators, Select Agents <input type="checkbox"/> Targeted Immune Modulators, TNF Inhibitors <input type="checkbox"/> Tetracyclines <input type="checkbox"/> Thiazolidinediones and Combination Agents <input type="checkbox"/> Thrombocytopenia Agents <input type="checkbox"/> Triglyceride Lowering Agents <input type="checkbox"/> Urinary Tract Antispasmodics
---	---